Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acarix AB (publ) (ACARIX.ST)
SEK0.25
0.00 (-1.39%)
SE STO Healthcare Medical - Devices
Address
Jungmansgatan 12 211 19
Malmö, SE
Malmö, SE
CEO
Aamir Mahmood
Website
acarix.com
IPO
2016-12-19
ISIN SE0009268717
Also trades on
Other OTC · ACIXF (USD)
Stockholm Stock Exchange · ACARIX.ST (SEK)
Description
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADScor System, an exceptionally sensitive, non-invasive analytical device designed for the detection of coronary artery disease. Founded in 2009, Acarix AB (publ) maintains its headquarters in Malmö, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK0.25
0.00 (-1.39%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
-0.21
Float Shares
399.94M
Free Float %
35.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.85% | +3.45% | -8.94% | -10.30% | -1.10% | +0.00% | +14.65% | -43.81% | -81.25% | -97.55% | -97.55% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.25
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.10
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+18.7% ★ Q1'26: +40.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+40.6% ★ Q1'26: +40.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-666.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-652.3% Q1'26: -348.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-241.3% Q1'26: -302.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+22.4% Q1'26: +4.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
638.0K
est: 656.0K (-2.7%)
|
1.02M
est: 1.29M (-20.3%)
|
1.86M
est: 1.81M (+2.5%)
|
2.17M
est: 4.11M (-47.1%)
|
3.76M
est: 6.00M (-37.3%)
|
5.82M
est: 7.00M (-16.8%)
|
6.24M
est: 11.00M (-43.3%)
|
6.20M
est: 7.00M (-11.4%)
|
7.36M
est: 6.80M (+8.3%)
|
19.10M
19.10M – 19.10M
+180.9% YoY
|
69.50M
69.50M – 69.50M
+263.9% YoY
|
145.20M
145.20M – 145.20M
+108.9% YoY
|
286.90M
286.90M – 286.90M
+97.6% YoY
|
| EBITDA |
-29.30M
est: -656.0K (-4,366.9%)
|
-41.99M
est: -1.29M (-3,167.8%)
|
-44.58M
est: -1.81M (-2,360.9%)
|
-40.29M
est: -4.11M (-881.5%)
|
-50.52M
est: -6.00M (-742.0%)
|
-76.12M
est: -7.00M (-987.4%)
|
-77.12M
est: -11.00M (-601.1%)
|
-62.63M
est: -7.00M (-794.7%)
|
-44.54M
est: -6.80M (-554.9%)
|
-19.10M
-19.10M – -19.10M
-180.9% YoY
|
-69.50M
-69.50M – -69.50M
-263.9% YoY
|
-145.20M
-145.20M – -145.20M
-108.9% YoY
|
-286.90M
-286.90M – -286.90M
-97.6% YoY
|
| EBIT |
-30.64M
est: -656.0K (-4,570.9%)
|
-42.23M
est: -1.29M (-3,186.3%)
|
-46.38M
est: -1.81M (-2,460.2%)
|
-41.44M
est: -4.11M (-909.6%)
|
-51.66M
est: -6.00M (-761.0%)
|
-76.82M
est: -7.00M (-997.5%)
|
-77.71M
est: -11.00M (-606.4%)
|
-65.92M
est: -7.00M (-841.7%)
|
-48.01M
est: -6.80M (-606.1%)
|
-19.10M
-19.10M – -19.10M
-180.9% YoY
|
-69.50M
-69.50M – -69.50M
-263.9% YoY
|
-145.20M
-145.20M – -145.20M
-108.9% YoY
|
-286.90M
-286.90M – -286.90M
-97.6% YoY
|
| Net Income |
-29.78M
est: -438.30M (+93.2%)
|
-42.27M
est: -770.37M (+94.5%)
|
-46.46M
est: -775.39M (+94.0%)
|
-41.55M
est: -533.94M (+92.2%)
|
-51.80M
est: -624.38M (+91.7%)
|
-76.99M
est: -556.38M (+86.2%)
|
-77.84M
est: -184.16M (+57.7%)
|
-66.19M
est: -112.68M (+41.3%)
|
-48.09M
est: 112.68M (-142.7%)
|
112.68M
112.68M – 112.68M
+0.0% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
| SGA |
25.88M
est: 6.21M (+316.9%)
|
30.89M
est: 12.16M (+154.0%)
|
27.59M
est: 17.14M (+60.9%)
|
28.56M
est: 38.85M (-26.5%)
|
33.03M
est: 56.79M (-41.8%)
|
53.34M
est: 66.25M (-19.5%)
|
54.33M
est: 104.11M (-47.8%)
|
46.58M
est: 54.68M (-14.8%)
|
36.02M
est: 53.11M (-32.2%)
|
149.19M
149.19M – 149.19M
+180.9% YoY
|
542.86M
542.86M – 542.86M
+263.9% YoY
|
1.13B
1.13B – 1.13B
+108.9% YoY
|
2.24B
2.24B – 2.24B
+97.6% YoY
|
| EPS |
-0.65
est: -0.48 (-36.6%)
|
-0.66
est: -0.84 (+21.1%)
|
-0.73
est: -0.84 (+13.3%)
|
-0.39
est: -0.58 (+32.7%)
|
-0.33
est: -0.68 (+51.3%)
|
-0.31
est: -0.60 (+48.7%)
|
-0.16
est: -0.20 (+20.0%)
|
-0.07
est: -0.10 (+28.1%)
|
-0.04
est: 0.10 (-142.7%)
|
0.10
0.10 – 0.10
+0.0% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-48.98M
OE per share TTM
-0.04
Owner's Yield
-15.48%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
13.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-60.0K
Shares Outstanding
1.12B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aamir Mahmood | President & Chief Executive Officer | 5M | male |
| Christian Lindholm | Chief Financial Officer & Executive Vice President | 2M | male |
| Beji George | Head of Global Strategy & Therapy Development | — | male |
| Carma Connely | Head of Operations & Customer Excellence | — | female |
| George Chrysant | Chief Medical Advisor | — | — |
| Jeffrey Rudd | Head of US Finance | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACARIX.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
